Loading clinical trials...
Loading clinical trials...
Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)
Conditions
Interventions
cisplatin
gemcitabine hydrochloride
Locations
147
United States
Hembree Mercy Cancer Center at St. Edward Mercy Medical Center
Fort Smith, Arkansas, United States
City of Hope Comprehensive Cancer Center
Duarte, California, United States
Tibotec Therapeutics - Division of Ortho Biotech Products, LP
Marysville, California, United States
Valley Medical Oncology Consultants - Pleasanton
Pleasanton, California, United States
Sutter Cancer Center at Roseville Medical Center
Roseville, California, United States
Sutter Cancer Center
Sacramento, California, United States
Start Date
November 1, 2008
Primary Completion Date
April 1, 2016
Completion Date
April 1, 2016
Last Updated
March 6, 2020
NCT06043817
NCT05671510
NCT07177937
NCT06426511
NCT03563976
NCT06498635
Lead Sponsor
SWOG Cancer Research Network
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions